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Estrogen prevents osteoporotic bone loss by
attenuating bone resorption; however, the
molecular basis for this is unknown. Here, we
report a critical role for the osteoclastic estro-
gen receptor a (ERa) in mediating estrogen-
dependent bone maintenance in female mice.
We selectively ablated ERa in differentiated
osteoclasts (ERaDOc/DOc) and found that
ERaDOc/DOc females, but not males, exhibited
trabecular bone loss, similar to the osteoporotic
bone phenotype in postmenopausal women.
Further, we show that estrogen induced apo-
ptosis and upregulation of Fas ligand (FasL)
expression in osteoclasts of the trabecular
bones of WT but not ERaDOc/DOc mice. The
expression of ERa was also required for the
induction of apoptosis by tamoxifen and estro-
gen in cultured osteoclasts. Our results support
a model in which estrogen regulates the life
span of mature osteoclasts via the induction
of the Fas/FasL system, thereby providing an
explanation for the osteoprotective function of
estrogen as well as SERMs.CINTRODUCTION
Bone remodeling is a dynamic metabolic process. The
destruction or ‘‘resorption’’ of pre-existing bone by mature
osteoclasts is followed by the formation of new bone by
osteoblasts. Osteoblasts are derived from pleiotropic
mesenchymal stem cells in the bone marrow. Mature os-
teoclasts are multinuclear, macrophage-like cells, derived
from hematopoietic stem cells also in the bone marrow.
Bone resorption and deposition are tightly coupled, and
their balance defines both bone mass as well as quality.
The regulation of bone remodeling is complex. A number
of systemic hormones and transcription factors directly
regulate the proliferation and differentiation of osteoblasts
and osteoclasts (Karsenty, 2006; Karsenty and Wagner,
2002; Rodan and Martin, 2000; Teitelbaum and Ross,
2003). Additionally, the indirect cellular communication
among groups of bone cells is also physiologically critical
for bone growth and remodeling (Martin and Sims, 2005;
Mundy and Elefteriou, 2006). The molecular and genetic
mechanisms governing bone cell fate have been inten-
sively studied; however, how the life span of bone cells
is determined on a molecular level remains elusive.
Estrogen is a key hormone in bone remodeling in several
species. The osteoprotective action of estrogen is demon-
strable in rodents and is clinically important in humans,
particularly older women (Chien and Karsenty, 2005;ell 130, 811–823, September 7, 2007 ª2007 Elsevier Inc. 811
Figure 1. Generation of Knockin Mice Selectively Expressing Cre in Mature Osteoclasts
(A) Illustration of the targeting strategy for insertion of the Cre gene into the mouse Cathepsin K (Ctsk) gene. A targeting vector was generated to
contain the Cre cDNA at the endogenous ATG start site, followed by a FRT (Flp-recombinase target)-flanked Neor cassette. The DT-A (diphtheria
toxin-A) gene was also inserted to avoid random integrations.
(B and C) Ctsk-Cre mice were then crossed with CAG-CAT-Z mice. b-galactosidase activity derived from the activated LacZ reporter gene was mon-
itored to test if expressed Cre excised the loxP sites in mature osteoclasts. LacZ expression patterns reflected the localization patterns of mature
osteoclasts in the developing bone at 16.5 days post coitum embryos and in the skeletal tissues of 7-day-old pups.
(D) The LacZ expression induced by Cre-mediated excision was also seen in osteoclasts attached to trabecular bone in the lumber vertebrae of
12-week-old mice.
(E) LacZ expression was induced during osteoclastogenesis. Osteoclast-like cells that differentiated from bone-marrow macrophages following
culture in the presence of M-CSF and RANKL were stained with TRAP (tartrate-resistant acid phosphatase), a mature osteoclast marker.812 Cell 130, 811–823, September 7, 2007 ª2007 Elsevier Inc.
Delmas, 2002; Raisz, 2005; Rodan and Martin, 2000).
Estrogen deficiency in postmenopausal women frequently
leads to osteoporosis, the most common skeletal dis-
order. Similarly, ovariectomy clearly produces an osteo-
porotic bone phenotype in mice. Osteoporotic bone loss
is the result of high bone turnover in which bone resorption
outpaces bone deposition (Rodan and Martin, 2000;
Teitelbaum, 2007). This imbalance in bone turnover that
is induced by estrogen deficiency in women and female
rodents can be ameliorated with bio-available estrogens
including selective estrogen receptor modulators
(SERMs) (Riggs and Hartmann, 2003).
Estrogen and SERMs primarily act by regulating gene
transcription via estrogen receptors (ERa, ERb) (Couse
and Korach, 1999; Shang and Brown, 2002). ERs belong
to the nuclear receptor gene superfamily and act as
ligand-inducible transcriptional factors (Mangelsdorf
et al., 1995). ER dimers directly or indirectly associate
with specific DNA elements in the target gene promoter
(Shang and Brown, 2002) and control transcription
through reorganizing chromatin structure and histone
modifications (Belandia and Parker, 2003). Genetic mouse
models (KO mice) lacking ERa (ERa/) and ERb (ERb/)
provide insights into ER function (Mueller and Korach,
2001; Windahl et al., 2002). In mice, though ERa appears
to be the major receptor in most estrogen target tissues
including bone (Sims et al., 2003), neither clear bone
loss nor high bone turnover is detectable in ERa single
or ERa/ERb double-KO females (Syed and Khosla, 2005;
Windahl et al., 2002). This unexpected maintenance of
bone mass in female mutants is presumed to be due to
unphysiologically elevated levels of other osteoprotective
hormones, like androgens. Systemic defects in the hypo-
thalamus caused by ER inactivation appear to impair the
negative feedback system of hormone production (Syed
and Khosla, 2005). This leads to an excess in estrogen
precursors, notably androgens. In fact, the anabolic
effects of androgens mediated by the androgen receptor
(AR) are evident in female mice (Kawano et al., 2003;
Sims et al., 2003). In males, estrogen is also osteoprotec-
tive, as is evident by the development of osteopenia in
male patients genetically deficient in ERa (Smith et al.,
1994) or aromatase activity (Simpson and Davis, 2001).
Thus, irrespective of the accumulating clinical and basic
research data on the osteoprotective actions of estrogen
and SERMs, the molecular basis of this osteoprotection
in females remains elusive.
To study the molecular interactions behind the antibone
resorptive actions of estrogen in women and female ani-
mals, we genetically ablated ERa in mature osteoclasts
(ERaDOc/DOc). Selective ablation of ERa in differentiated
osteoclasts (ERaDOc/DOc) was accomplished by crossing
a Cathepsin K-Cre knockin mouse with a floxed ERa
mouse. This resulted in clear trabecular bone loss andChigh bone turnover associated with increased osteoclast
numbers in females but not in males. In the female
mutants, further bone loss following ovariectomy was
not significant and recovery by estrogen was ineffective
in the trabecular areas of long bones and lumbar vertebral
bodies. Upregulated expression of Fas ligand (FasL) gene,
and increased apoptosis in differentiated osteoclasts by
estrogen was found in the intact bone of wild-type females
but undetectable in ERaDOc/DOc females. Induction of
FasL and apoptosis by estrogen as well as a SERM also
required ERa in cultured osteoclasts. Thus, we propose
that the osteoprotective actions of estrogen and SERMs
are mediated at least in part through osteoclastic ERa in
trabecular bone, and the life span of mature osteoclasts
is regulated through the activation of the FasL signaling.
RESULTS
Generation of Osteoclast-Specific ERa Gene
Disruption by Knocked-In Cre in the Cathepsin
K Gene
To specifically disrupt ERa gene in mature osteoclasts, we
knocked in Cre into the gene locus of Cathepsin K
(CtskCre/+) (Figures 1A, S1A, and S1B), a gene known to
be expressed in differentiated osteoclastic cells arising
from hematopoietic stem cells. This gene is functionally
indispensable for mature osteoclasts (Saftig et al., 1998).
Only one copy appears enough to support normal bone
formation and bone turnover, since heterozygous mutant
mice of Cathepsin K (Ctsk+/) have no obvious bone
phenotype (Gowen et al., 1999; Li et al., 2006; Saftig
et al., 1998) . Clear, bone-specific expression of the Cre
transcript in the adult CtskCre/+ mice was observed in the
tested tissues (Figure S1C). To confirm Cre protein
expression, the CtskCre/+ mice were crossed with tester
mice (CAG-CAT-Z). These mice were genetically engi-
neered to express b-galactosidase by excision of the tran-
scribed stop sequence in front of the b-galactosidase
gene (LacZ) in cells expressing Cre (Sakai and Miyazaki,
1997). b-galactosidase expression visualized by LacZ
staining was observed in the bones of 16.5 dpc embryos
and 7-day-old pups of CtskCre/+; CAG-CAT-Z mice.
Expression patterns were consistent with the appearance
and skeletal localization of functionally mature osteoclasts
(Figures 1B and 1C). Histochemical staining of LacZ in the
lumbar vertebrae of 12-week-old mice was localized in
multinuclear osteoclasts (Figure 1D) but not seen in oste-
oblasts and osteocytes (Figure S1D) and the hypothala-
mus (Figure S1E). Since Cathepsin K gene expression is
evident in differentiated osteoclasts (Saftig et al., 1998),
we used an in vitro culture cell system to test whether
Cre expression was driven by the endogenous promoter
that is induced at the time of osteoclast differentiation.
Osteoclast-precursor cells derived from bone marrow(F) The growth curve of ERaDOc/DOc mice was indistinguishable from that of the control mice. Data are represented as mean ± SEM.
(G) Serum hormone levels were normal in 12-week-old ERaDOc/DOc (filled column) versus ERa+/+ (open column) mice (n = 10–11 animals per
genotype). Data are represented as mean ± SEM.ell 130, 811–823, September 7, 2007 ª2007 Elsevier Inc. 813
were cytodifferentiated for 1 week in the presence of
M-CSF (macrophage colony stimulating factor) and
RANKL (receptor activator of NFkB ligand) (Koga et al.,
2004). TRAP-positive osteoclasts emerged after 3 days
of culture (Figure 1E). The number of TRAP-positive oste-
oclasts and the number of LacZ-expressing cells simulta-
neously increased. In the contrast, the LacZ expression
was not detected in primary cultured osteoblasts derived
from the calvaria (Figure S1F). In view of both our in vivo
and in vitro observations, we conclude that the CtskCre/+
mouse line expresses Cre in differentiated osteoclasts.
Moreover, estrogen response in bone mass control was
not distinguishable in between CtskCre/+ and Ctsk+/+
mice (Figure S2A).
We then crossed floxed ERa mice (Dupont et al., 2000)
with CtskCre/+ mice to disrupt ERa in differentiated osteo-
clasts (ERaDOc/DOc). Excision of theERa gene (Figure S1G)
was confirmed by Southern blotting of DNA from adult
female and male (data not shown) bone as well as in
cultured mature osteoclasts (Figure S1H). No overt differ-
ences were observed in the growth curve, reproduction,
or tissues for up to 12 weeks of age (Figure 1F) between
the CtskCre/+; ERa+/+ (ERa+/+) and the CtskCre/+; ERaflox/flox
(ERaDOc/DOc) mice, with the exception of the female
bones. Serum levels of sex hormones and bone remodel-
ing regulators such as IGF-I, leptin, and follicle-stimulating
hormone (Sun et al., 2006; Takeda et al., 2002) appeared
unchanged in both male and female ERaDOc/DOc mice at
12 weeks (Figure 1G).
Osteopenia Occurred in Osteoclast-Specific ERa
KO Females But Not Males
The 12-week-old ERaDOc/DOc females exhibited a clear
reduction in bone mineral density (BMD) in the femurs (Fig-
ures 2A–2C) and tibiae (data not shown) when compared
with ERa+/+ mice. Though cortical bone appeared unaf-
fected, trabecular bone loss (Figure 2A) with significant
reduction of trabecular bone volume (BV/TV) (Figure 2F)
was clearly seen. This is similar to the osteoporotic abnor-
malities observed in women during natural menopause or
following ovariectomy (Delmas, 2002; Tolar et al., 2004).
However, unlike men deficient in aromatase or ERa activity
(Simpson and Davis, 2001; Smith et al., 1994), ERaDOc/DOc
males unexpectedly exhibited no clear bone loss even
in the trabecular areas (Figures 2A–2C). In ERaDOc/DOc
females, both the bone-formation rate, estimated by
double-calcein labeling (Figure 2D), as well as the bone-
resorption rate, estimated from TRAP-positive differenti-
ated osteoclast numbers (Figure 2E), were increased, indi-
cating high bone turnover. Histomorphometric analyses of
ERaDOc/DOc females supported the observation of accel-
erated bone resorption, as increased numbers of osteo-
clasts (Oc. S/BS and N. Oc/BS) were observed together
with more eroded bone surface (ES/BS in Figure 2F).
Bone formation was also enhanced as the rates of mineral
apposition (MAR) and bone formation (BFR/BS) were both
upregulated without an increase in osteoblast numbers
(Ob.S/BS) (Figure 2F). Thus, considering all of these find-814 Cell 130, 811–823, September 7, 2007 ª2007 Elsevier Inc.ings, it is conceivable that the increased number of differ-
entiated osteoclasts following ERa ablation accelerates
bone resorption over formation, leading to bone loss in
the trabecular areas.
No Further Bone Loss Results from Estrogen
Deficiency in ERaDOc/DOc Females
To verify whether osteoclastic ERa indeed mediates
osteoprotective estrogen actions, estrogen action was
investigated by ovariectomy (OVX) of 12-week-old female
mice. As expected, OVX in ERa+/+ females resulted in sig-
nificantly reduced BMD particularly in the trabecular bone
(Figures 3A and 3B) but not in the cortical bone (Figure 3C).
Consistent with previous reports, (Kimble et al., 1995;
Teitelbaum and Ross, 2003), estrogen deficiency follow-
ing OVX upregulated the serum levels of cytokines like
TNFa and IL-1a (Figure 3D). These cytokines enhance
bone resorption through stimulation of osteoclastogene-
sis, leading to the loss of bone mass (Teitelbaum and
Ross, 2003). OVX did not further reduce BMD or trabecu-
lar bone volume of the femurs of ERaDOc/DOc females
(Figure 3B) nor affect increased number of TRAP-positive
osteoclasts (see lower panel in Figure 3A) despite upregu-
lation of serum cytokines. This suggests that the expres-
sion of cytokines known to regulate bone resorption is
not under the control of osteoclastic ERa.
Estrogen Treatment Failed to Rescue the
Osteoporotic Bone Phenotype of ERaDOc/DOc Mice
Estrogen treatment by estrogen pellet implantation (OVX +
E2) for 2 weeks after OVX in ERa+/+ mice elicited a dra-
matic increase in bone mass in both the trabecular and
cortical areas of the femurs (data not shown) and lumbar
vertebral bodies (Figure 4A). Estrogen action during E2
treatment in female mutants (ERaDOc/DOc) was not as
pronounced as in the ERa+/+ females (Figures 4A and
4B), and the increase in the trabecular portions of the
distal femurs was slight (data not shown). Histomor-
phometric analysis of the lumbar vertebral bodies
(Figure 4B) supported the idea that E2 treatment in the
female mutants was not sufficient to suppress accelerated
bone resorption. These in vivo findings in the ERaDOc/DOc
females suggest that in at least the trabecular areas of the
long bones and lumbar vertebral bodies, the osteoprotec-
tive estrogen action is primarily mediated via osteoclastic
ERa inhibiting bone resorption.
To further test this hypothesis, we investigated ERa
protein expression in mature osteoclasts from trabecular
bone. Few reports document osteoclastic expression of
ERa protein and an estrogen response in both intact
animals and in in vitro cultured osteoclasts (Bland,
2000). We therefore reasoned that ER expression ceases
during differentiation into mature cells from primary
cultures of osteoclast precursors, similar to that observed
in other primary culture cell systems such as avian oviduct
cells, in which ERa protein expression is drastically
decreased during culture (Kato et al., 1989). Using highly
sensitive immunohistochemistry, we investigated whether
Figure 2. High Bone Turnover Osteopenia Was Observed in ERaDOc/DOc Females But Not Males
(A) Soft X-ray images of femurs from 12-week-old CtskCre/+; ERaflox/flox (ERaDOc/DOc) mice.
(B) Three-dimensional computed tomography images of the distal femurs and axial sections of distal metaphysis from representative 12-week-old
CtskCre/+; ERa+/+ (ERa+/+) and ERaDOc/DOc mice.
(C) BMD of each of 20 equal longitudinal divisions of femurs from 12-week-old ERa+/+ and ERaDOc/DOc mice. (n = 10–11 animals per genotype;
Student’s t test, *p < 0.05; **p < 0.01; ***p < 0.001). Data are represented as mean ± SEM.
(D) Bone formation was also accelerated in ERaDOc/DOc females when two calcein-labeled mineralized fronts visualized by fluorescent micrography
were measured in the proximal tibia of 12-week-old mice.
(E) The number of TRAP-positive osteoclasts in the lumbar spine of female mice was increased by selective disruption of ERa in osteoclasts, indi-
cating enhanced bone resorption.
(F) Bone turnover parameters as measured by dynamic bone histomorphometry after calcein labeling indicated high bone turnover in ERaDOc/DOc
females. Parameters are measured in the proximal tibia of 12-week-old ERa+/+ (open column) and ERaDOc/DOc (filled column) mice. BV/TV: bone
volume per tissue volume. ES/BS: eroded surface per bone surface. Oc.S/BS: osteoclast surface per bone surface. N.Oc/BS: osteoclast number
per bone surface. MS/BS: mineralizing surface per bone surface. Ob.S/BS: osteoblast surface per bone surface. MAR: mineral apposition rate.
BFR/BS: bone formation rate per bone surface (n = 10–11 animals per genotype; Student’s t test, *p < 0.05; **p < 0.01; ***p < 0.001). Data are
represented as mean ± SEM.ERa protein expresses in differentiated osteoclasts in the
bone tissues of femur sections from 12-week-old mice.
ERa protein expression appeared abundant in osteoblasts
and osteocytes of femur sections (Figure 4C) as well as
hypothalamus (Figure S2B) from 12-week-old mice, in
agreement with a previous report (Zaman et al., 2006). Like-
wise, expression levels of ERa in primary cultured
osteoblasts derived from calvaria of ERaDOc/DOc females
appeared unaffected (Figure S2C). In contrast, in differenti-
ated osteoclasts of the same femur sections, ERa expres-
sion was definitely detectable but very low in theERa+/+but
undetectable in ERaDOc/DOc females (Figure 4C).CSignaling by Osteoclastogenic Factors
and Osteoclastogenesis Is Intact in Osteoclasts
Deficient in ERa
It is possible that the osteoprotective function of osteo-
clastic ERa inhibits osteoclastogenesis. To address this
issue, osteoclastogenesis was tested in cultured osteo-
clasts derived from bone-marrow cells of ERaDOc/DOc
mutants. In this cell culture system, a possible contribu-
tion of contaminated immune cells and stromal cells could
be excluded, since osteoclastogenesis is only inducible
by M-CSF treatment followed by M-CSF + RANKL
(Koga et al., 2004).ell 130, 811–823, September 7, 2007 ª2007 Elsevier Inc. 815
Figure 3. No Further Bone Loss of
ERaDOc/DOc Females by Ovariectomy
(A) Distal femoral micro CT analysis and lumbar
vertebral bone histomorphometrical analysis
of sham-operated or ovariectomized (OVX)
12-week-old ERa+/+ and ERaDOc/DOc mice
(*p < 0.05 compared to ERa+/+ sham group).
Two weeks after OVX, the bone phenotype
was analyzed.
(B) BMD of the distal femurs within each group
are described in Figure 3A (*p < 0.05; N.S., not
significant). Data are represented as mean ±
SEM.
(C) Cortical thickness evaluation from micro CT
analysis of femurs within each group described
in Figure 3A. Data are represented as mean ±
SEM.
(D) The levels of TNFa, IL-1a, and IL-6 in the
bone-marrow cells culture media and serum
RANKL (*p < 0.05 compared to each sham
group). Data are represented as mean ± SEM.816 Cell 130, 811–823, September 7, 2007 ª2007 Elsevier Inc.
Figure 4. Estrogen treatment failed to
reverse trabecular bone loss of ovariec-
tomized ERaDOc/DOc females
(A) von kossa staining of lumbar vertebral bod-
ies of ovariectomized ERa+/+ and ERaDOc/DOc
mice treated with or without 17b-estradiol
(0.83 mg/day) for 2 weeks (+E2) groups.
(B) Bone histomorphometrical analyses of
the lumber vertebral bodies of 12-week-old
ovariectomized ERa+/+ (left columns) and
ERaDOc/DOc (right columns) mice with (filled
columns) or without (open columns) E2 treat-
ment for 2 weeks (*p < 0.05 compared with
E2-treated ovariectomized ERaDOc/DOc mice).
BV/TV: bone volume per tissue volume. ES/
BS: eroded surface per bone surface. Oc.S/
BS: osteoclast surface per bone surface.
N.Oc/BS: osteoclast number per bone sur-
face. MS/BS: mineralizing surface per bone
surface. Ob.S/BS: osteoblast surface per
bone surface. MAR: mineral apposition rate.
BFR/BS: bone formation rate per bone surface.
Data are represented as mean ± SEM.
(C) Immunochemical identification of ERa
(brown) in TRAP-positive (red) differentiated
osteoclasts. The femurs of 12 week-old mice
were used for the immunodetection of ERa in
bone cells. All labels were abolished when
the primary antibody was preadsorbed with
the immunizing peptide (negative control).The number of TRAP-positive osteoclasts differentiated
from the bone-marrow cells of ERaDOc/DOc females was
almost the same as that from ERa+/+ females (Figure 5A)
and males (data not shown). The differentiated ERaDOc/DOc
osteoclasts had typical osteoclastic features, including
the characteristic cell shape, TRAP-positive, multiple
nuclei, and actin-ring formation, and were indistinguish-
able from the ERa+/+ osteoclasts (Figure 5B).
The expression levels of the prime osteoclastogenic
transcription factors, c-fos and NFATc1, were unaltered
by ERa deficiency in differentiated osteoclasts (Fig-
ure 5C). Furthermore, responses to RANKL in intracellular
signaling, as represented by phosphorylation of p38Cand IkB, were unaffected in ERaDOc/DOc osteoclasts
from females (Figure 5D) as well as males (data not
shown). In light of these findings, it is unlikely that acti-
vated ERa in osteoclastic cells attenuates osteoclasto-
genesis.
Activation of the Fas/FasL System by Estrogen
in Intact Bone Is Impaired by Osteoclastic
ERa Deficiency
To examine osteoclastic ERa function in intact bone, DNA
microarray analysis following real-time RT-PCR of RNA
from the femurs of ovariectomized ERaDOc/DOc females
treated with or without estrogen, was performed. Duringell 130, 811–823, September 7, 2007 ª2007 Elsevier Inc. 817
Figure 5. ERa Deficiency Did Not Affect
Osteoclastogenesis
(A) TRAP-positive multinucleated cell count at
3 days after RANKL stimulation, cultured in
24-well plates (n = 6, N.S., not significant).
Data are represented as mean ± SEM.
(B) TRAP staining and actin ring formation of
RANKL induced primary cultured osteoclasts
from bone-marrow cells of ERa+/+ and
ERaDOc/DOc mice.
(C) RT-PCR analysis of genes related to osteo-
clastogenesis.
(D) Western blot analysis of phosphorylated
p38, JNK, and IkB of primary cultured bone-
marrow cells stimulated with or without
100 ng/ml of RANKL for 15 min.the search for candidate ERa target genes in bone by DNA
microarray analysis (Figure S3), we found that a number of
apoptosis-related factors were regulated by estrogen in
the intact bone of ERa+/+ females but dysregulated in
ERaDOc/DOc females. This observation is consistent with
a previous report of estrogen-induced apoptosis of
mature osteoclasts (Kameda et al., 1997). Real-time RT-
PCR to validate the estrogen regulations of the candidate
genes revealed that gene expression of FasL, an apoptotic
factor, was responsive to E2 (Figure 6A). Estrogen treat-
ment (+E2) indeed induced expression of FasL protein in
bone of ovariectomized ERa+/+, but this induction was
not obvious in ovariectomized ERaDOc/DOc mice (Figures
6B and 6C). Reflecting FasL induction by estrogen, estro-
gen-induced apoptosis (as observed by the TUNEL assay)
in TRAP-positive mature trabecular osteoclasts in the
distal femurs of the ERa+/+ mice was detected, but this
E2 response was abolished in the ERaDOc/DOc mice
(Figure 6D). Furthermore, in mice lacking functional FasL
(FasLgld/gld), neither enhanced bone resorption nor bone
mass loss was induced by ovariectomy (Figures 6E
and 6F).
Osteoclastic ERa Mediates Estrogen-Induced
apoptosis by FasL
The expression level of ERa protein in differentiated
osteoclasts derived from bone marrow cells was very
low, but induction of FasL gene expression was also
detectable in the cultured osteoclasts of ERa+/+ females
as well as males (Figure 7A). However, this E2 response
was impaired in cultured osteoclasts from ERaDOc/DOc
females (Figure 7A). It is notable that such responses are
also induced by tamoxifen (Figure 7C), which is an osteo-
protective SERM (Harada and Rodan, 2003). ERa overex-
pression augmented FasL gene expression in response to
estrogen in cultured osteoclasts from ERaDOc/DOc females818 Cell 130, 811–823, September 7, 2007 ª2007 Elsevier Inc.(Figure S4A). In primary cultured calvarial osteoblasts from
females as well as males (Suzawa et al., 2003), FasL gene
induction by E2 and tamoxifen was also seen; however, it
was not accompanied by increased apoptosis (data not
shown). Thus, it appears that estrogen-induced apoptosis
in osteoclasts is mediated by FasL expression in osteo-
clasts in the trabecular bone areas, presumably as well
as in osteoblasts in cortical bone areas. As expected,
the cell number of TUNEL-positive osteoclasts was
increased by E2 in the cultured osteoclasts from ERa+/+
females, but E2-induced apoptosis was undetectable in
ERaDOc/DOc osteoclasts (Figure 7B). Consistent with
FasL-induced apoptosis, Fas gene expression was ob-
served (Figure 7D), but it was likely that Fas expression
did not require ERa function (Figures S4B and S4C).
Expression levels of Fas and ERa as well as E2 response
in apoptosis appeared to fluctuate during osteoclast dif-
ferentiation (Figures S4B–S4D); however, in FasL mutant
(FasL gld/gld) females, the E2-induced apoptosis was abol-
ished (Figure S4E). These findings suggest that activated
ERa in differentiated osteoclasts induces apoptosis
through activating FasL/Fas signaling. This leads to sup-
pression of bone resorption through truncating the already
short life span of differentiated osteoclasts (Teitelbaum,
2006).
DISCUSSION
Selective ablation of ERa in mature osteoclasts in female
mice shows that the osteoprotective effect of estrogen is
mediated by osteoclastic ERa, at least in the trabecular
regions of the tibiae, femur, and lumbar vertebrae of fe-
male mice. Activated ERa by estrogen as well as SERMs
appears to truncate the already short life span (estimated
at 2 weeks) of differentiated osteoclasts by inducing
apoptosis through activation of the Fas/FasL system.
Figure 6. Activated ERa Induced Fas Ligand Expression and Apoptosis in Differentiated Osteoclasts of Intact Bone
(A) Real-time RT-PCR analysis of Fas and FasL. Expression levels in bones from E2-treated ovariectomized ERa+/+ (open column) and ERaDOc/DOc
(filled column) were compared with the ovariectomized groups of each genotype without E2 administration (*p < 0.05 compared to ERa+/+). Data are
represented as mean ± SEM.
(B) Immunohistochemical analysis of anti-FasL with TRAP staining of the sections from the distal femurs of E2-treated ovariectomized ERa+/+ and
ERaDOc/DOc mice. Brawny stained cells are anti-FasL positive.
(C) Anti-FasL western blot analysis of proteins obtained from femurs of ovariectomized ERa+/+ and ERaDOc/DOc mice treated with or without E2, using
anti-b-actin as internal control.
(D) TUNEL staining with TRAP staining of the sections from the distal femurs of E2-treated ovariectomized ERa+/+ and ERaDOc/DOc mice. Arrowheads
indicate both TUNEL (brown)- and TRAP-positive staining cells.
(E) Bone histomorphometrical analysis of sham-operated or ovariectomized FasLgld/gld mice.
(F) BMD of the distal femurs of sham operated or ovariectomized FasLgld/gld mice. Data are represented as mean ± SEM.This attenuates bone resorption. This idea is supported by
previous observations that estrogen deficiency following
menopause or ovariectomy leads to high bone turnover,
particularly in the trabecular areas, as bone is rapidly
lost through enhanced resorption (Delmas, 2002; Tolar
et al., 2004). Thus, estrogen treatment leads to recovery
from osteopenia by reducing resorption (Delmas, 2002;
Rodan and Martin, 2000), partly by the induction of osteo-
clast cell death.In contrast to the osteopenia seen in the ERaDOc/DOc
females, the ERaDOc/DOc male mice unexpectedly had
no bone loss. The male mice still demonstrated an ERa-
mediated induction of FasL in response to estrogen with
subsequent apoptosis of osteoclasts (Figure 7). Both
male mice with a deficiency of aromatase that are unable
to locally produce estrogen from testosterone and men
with a genetic mutation in the ERa gene suffer from os-
teoporosis (Smith et al., 1994). Considering that theCell 130, 811–823, September 7, 2007 ª2007 Elsevier Inc. 819
Figure 7. Estrogen-Induced FasL Expression and Apoptosis
Required ERa in Cultured Osteoclasts
(A) Real-time RT-PCR analysis of FasL expression using total RNA
obtained from in vitro primary cultured osteoclasts of each genotype
at 3 days after RANKL stimulation, treated with or without E2
(108 M) for 4 hr (*p < 0.05 compared to the group treated without
E2). Data are represented as mean ± SEM.820 Cell 130, 811–823, September 7, 2007 ª2007 Elsevier Inc.markedly elevated levels of testosterone in ERa KO
females may be potent enough to maintain normal bone
turnover (Syed and Khosla, 2005), it is likely that the acti-
vated AR might be functionally sufficient in male mice to
compensate for the ERa deficiency in bone (Kawano
et al., 2003). However, species differences in the osteo-
protective action of sex steroid hormones still need to
be carefully addressed.
Fas/FasL system-mediated apoptotic induction of oste-
oclasts by estrogen may well be a part of the mechanism
for the antiresorptive action of estrogen and SERMs in
trabecular bone areas (Delmas, 2002; Rodan and Martin,
2000; Simpson and Davis, 2001; Syed and Khosla, 2005;
Tolar et al., 2004). Regulation of osteoclast differentiation
is tightly coupled to osteoblastic function in terms of
cytokine production and cell-cell contact (Karsenty and
Wagner, 2002; Martin and Sims, 2005; Mundy and Elefter-
iou, 2006; Teitelbaum and Ross, 2003). Indeed, upregula-
tion of osteoclastogenic cytokines by ovariectomy was
unaffected in ERaDOc/DOc females. Considering the obser-
vation that cortical bone mass is increased in ovariecto-
mized ERaDOc/DOc females during estrogen treatment, it
is conceivable that the antiresorptive estrogen action in
cortical bone is also mediated by osteoblastic ERa. In
this regard, FasL induction by estrogen in osteoblasts
may contribute to the osteoprotective estrogen action,
and FasL gene induction by estrogen was in fact detected
in primary cultured osteoblasts from female calvaria by us
as well as another group (S. Krum and M. Brown, personal
communication). Thus, similar experiments in which ERa
is selectively ablated in osteoblasts are needed to define
the role of ERa in these cells.
In osteoclastic cells, expression of the FasL gene, which
leads to apoptosis, appears to be positive controlled by
activated ERa. Not surprisingly, a direct binding site for
ERa has been mapped in the FasL gene locus (S. Krum
and M. Brown, personal communication). An osteoclast-
and cell-differentiation stage-specific mechanism may
underlie this gene induction in the FasL gene promoter.
A recent study demonstrated that ERa recruitment to
specific promoter sites of given ERa target genes was
cell-type specific (Carroll et al., 2005). Thus, there is signif-
icant impetus to identify the osteoclastic factor that
associates with ERa in the FasL gene promoter. Such
identification will lead to a better understanding of the mo-
lecular basis of the osteoprotective estrogen action and
provide a target against which to develop SERMs of
greater effectiveness.
(B) Apoptotic cells were defined as those with TUNEL-positive nuclei
among TRAP-positive multinucleated primary cultured osteoclasts
treated with or without E2 (108 M) for 12 hr in 96-well plates
(*p < 0.05 compared to the group treated without E2). Data are repre-
sented as mean ± SEM.
(C) FasL expression in each genotypic female osteoclastic cells treated
with or without Tam (106 M) (*p < 0.05 compared to the group treated
without Tam). Data are represented as mean ± SEM.
(D) Expression of Fas was measured as described in the legend of
Figure 7A. Data are represented as mean ± SEM.
EXPERIMENTAL PROCEDURES
Ctsk-Cre Construction and Generation of the Knockin
Mouse Lines
An RP23-422n18 BAC clone containing the mouse Ctsk gene was
purchased from Invitrogen (Carlsbad, CA). The FRT-Kanr/Neor-FRT
and nlsCre fragments were obtained from plasmids pSK2/3-FRT-
Neo and pIC-Cre. Two homologous arms of 500 bp from the Ctsk
gene were inserted into both sides of the nlsCre-FRT-Kanr/Neor-FRT
cassette in the pSK2/3-FRT-Neo plasmid. The nlsCre-FRT-Kanr/
Neor-FRT cassette was introduced into the endogenous ATG start
site of the Ctsk gene by recombineering approaches (Copeland
et al., 2001). Targeted BAC was reduced in size from 189 kb to
26 kb and subcloned into the pMC1-DTpA vector by the gap-repair
method. The targeted TT2 ES clones were selected after positive-
negative selection with G418 and DT-A with Southern analysis, then
aggregated with single eight-cell embryos from CD-1 mice (Yoshizawa
et al., 1997). Chimeric mice were then crossed with a general deleter
mouse line, ACTB-Flpe (Jackson Laboratory), to remove the Kanr/
Neor cassette. The Ctsk-Cre mice (CtskCre/+), originally on a hybrid
C57BL/6 and CBA genetic background, were backcrossed for four
generations into a C57BL/6J background. FasLgld/gld mice were also
purchased from Jackson Laboratory.
Analysis of Cre Recombinase Activities
Expression of the Cre transcript was detected by RT-PCR. Southern
analysis using a Cre cDNA probe was performed with total RNA
extracted from 12-week-old mice. To evaluate the specificity and effi-
ciency of Cre-mediated recombination, we mated theCtskCre/+ mice to
CAG-CAT-Z reporter mice (kindly provided by J. Miyazaki) (Sakai and
Miyazaki, 1997) and genotyped their offspring with Cre-specific
primers. b-galactosidase activity of the expressed LacZ gene driven
by the CAG promoter was expected to be detected in the given cells
expressing functional Cre recombinase.
In Vitro Osteoclastogenesis and Ligand Application
Bone-marrow cells derived from 8-week-old mice were plated in cul-
ture dishes containing a-MEM (GIBCO-BRL) with 10% FBS (JRH)
and 10 ng/ml M-CSF (Genzyme). After incubation for 48 hr, adherent
cells were used as osteoclast precursor cells after washing out the
nonadherent cells. Cells were cultured in the presence of 10 ng/ml
M-CSF and 100 ng/ml RANKL (Peprotech) to generate osteoclast-
like cells (Koga et al., 2004) for 3 days, so the total culture time was
5 days. Three days after RANKL stimulation, primary cultured osteo-
clasts were treated with 108 M of 17b-estradiol (E2) (Sigma-Aldrich
Co.) or 106 M 4-hydroxytamoxifen (Tam) (Sigma-Aldrich Co.) in
phenol-red free medium.
Generation of Osteoclast-Specific ERa KO Mice
The ERa conditional (ERaflox/flox) (Dupont et al., 2000) and null alleles
with a C57BL/6J background have been previously described.
ERaflox/flox mice were crossed with CtskCre/+ mice to generate
CtskCre/+; ERaflox/+ mice. CtskCre/+; ERa+/+ (ERa+/+) and CtskCre/+;
ERaflox/flox (ERaDOc/DOc) mice were obtained by crossing CtskCre/+;
ERaflox/+ with ERaflox/+ mouse lines.
Radiological Analysis
Bone radiographs of the femurs of 12-week-old CtskCre/+; ERaflox/flox
(ERaDOc/DOc) and CtskCre/+; ERa+/+ (ERa+/+) littermates were visualized
with a soft X-ray apparatus (TRS-1005: SOFTRON). BMD was
measured by DXA using a bone mineral analyzer (DCS-600EX:
ALOKA). Micro Computed Tomography scanning of the femurs was
performed using a composite X-ray analyzer (NX-CP-C80H-IL: Nit-
tetsu ELEX Co.) (Kawano et al., 2003). Tomograms were obtained
with a slice thickness of 10 mm and reconstructed at 12 3 12 pixels
into a 3D image by the volume-rending method (VIP-Station; Teijin
System Technology) using a computer.CAnalysis of Skeletal Morphology
Twelve-week-old CtskCre/+; ERaflox/flox (ERaDOc/DOc) and CtskCre/+;
ERa+/+ (ERa+/+) littermates were double labeled with subcutaneous
injections of 16 mg/kg of calcein (Sigma) at 4 and 2 days before sacri-
fice. Tibiae were removed from each mouse and fixed with 70% etha-
nol. They were stained with Villanueva bone stain for 7 days and
embedded in methyl-methacrylate (Wako) (Yoshizawa et al., 1997).
Frontal plane sections (5-mm thick) of the proximal tibia were cut using
a Microtome (LEICA). The cancellous bone was measured in the sec-
ondary spongiosa located 500 mm from the epiphyseal growth plate
and 160 mm from the endocortical surface (Kawano et al., 2003; Naka-
michi et al., 2003). Bone histomorphometric measurements of the tibia
were made using a semiautomatic image analyzing system (System
Supply) and a fluorescent microscope (Optiphot; Nikon). Similar
measurements of the lumbar vertebral bodies were done as previously
reported (Takeda et al., 2002). Standard bone histomorphometrical
nomenclatures, symbols, and units were used as described in the
report of the ASBMR Histomophometry Nomenclature Committee.
Ovariectomy and Hormone Replacement
Female CtskCre/+; ERaflox/flox (ERaDOc/DOc) and CtskCre/+; ERa+/+
(ERa+/+) littermates were ovariectomized or sham operated at 8–12
weeks of age for 2 weeks for all experiments, and slow releasing
pellets of E2 (0.83 mg/day) or placebo (Innovative Research, Sarasota,
FL) were implanted subcutaneously in the scapular region behind the
neck (Sato et al., 2004; Shiina et al., 2006).
Immunohistochemistry
Twelve-week-old CtskCre/+; ERaflox/flox (ERaDOc/DOc) and CtskCre/+;
ERa+/+ (ERa+/+) littermates were fixed with 4% PFA by perfusion. Serial
sections of the brain (20 mm thick) were divided into two groups and
used for single labeling for the ERa or thionin to allow determination
of the areas to be measured. Tibiae and femurs were decalcified in
10% EDTA for 2–4 weeks after fixation and then embedded in paraffin
sections. Sections were incubated in L.A.B. solution (Polysciences) for
30 min to retrieve antigen. The cooled sections were incubated in 1%
H2O2 for 30 min to quench endogenous peroxidase and then washed
with 1% Triton X-100 in PBS for 10 min. To block nonspecific antibody
binding, sections were incubated in blocking solution (DAKO) for 5 min.
Sections were then incubated with anti-ERa (Santa Cruz, CA) and anti-
FasL (Santa Cruz, CA) in blocking solution overnight at 4C. Staining
was then performed using the EnVision+ HRP System (Dako) and 3,
30-diaminobendizine tetrahydrochloride substrate (Sigma), counter-
stained with TRAP, dehydrated through an ethanol series and xylene,
before mounting (Sato et al., 2004).
ERa Overexpression
Two days after RANKL stimulation, an expression vector of mouse ERa
was tranfected into immature osteoclastic cells from ERaDOc/DOc mice
using Superfect (QIAGEN) as manufacture’s instruction.
Real-Time RT-PCR
One microgram of total RNA from each sample was reverse tran-
scribed into first-strand cDNA with random hexamers using Super-
script III reverse transcriptase (Invitrogen). Primer sets for all genes
were purchased from Takara Bio. Inc. (Tokyo, Japan). Real-time RT-
PCR was performed using SYBR Premix Ex Taq (Takara) with the
ABI PRISM 7900HT (Applied Biosystems) according to the manufac-
turer’s instructions. Experimental samples were matched to a standard
curve generated by amplifying serially diluted products using the same
PCR protocol. To correct for variability in RNA recovery and efficiency
of reverse transcription, Gapdh cDNA was amplified and quantified in
each cDNA preparation. Normalization and calculation steps were
performed as reported previously (Takezawa et al., 2007).ell 130, 811–823, September 7, 2007 ª2007 Elsevier Inc. 821
TUNEL/TRAP Staining
The TUNEL method was performed using the ApopTag Fluorescein In
Situ Apoptosis Detection Kit (CHEMICON international) according to
the manufacturer’s instructions with a slight modification. This was
followed by TRAP staining as previously reported (Kobayashi et al.,
2000).
Cytokine Assays
Bone marrow and blood were collected at 2 weeks after sham opera-
tion or ovariectomy. Bone-marrow cells were cultured for 3 days in
DMEM. The levels of TNFa, IL-1a, and IL-6 in the culture media and
serum RANKL were determined by ELISA (R&D Systems).
Western Blot
Osteoclast precursor cells were treated with or without 100 ng/ml of
soluble RANKL. After 15 minutes, cell extracts were harvested from
the cells using lysis buffer containing 100 mM Tris-HCl (pH 7.8),
150 mM NaCl, 0.1% Triton X-100, 5% protease inhibitor cocktail
(Sigma), and 5% phosphatase inhibitor cocktail (Sigma). An equivalent
amount of protein from each of the cell extracts and proteins of femoral
bone extracted using ISOGEN was loaded for SDS-PAGE and trans-
ferred to PVDF membranes (Amersham Biosciences). The membranes
were developed with enhanced chemiluminescence reagent (Amer-
sham Biosciences) (Ohtake et al., 2003). Phosphorylation of p38
MAPK and IkB were evaluated using antibodies purchased from Cell
Signaling Technology (Koga et al., 2004) and anti-FasL antibody was
purchased from Santa Cruz Biotechnology (sc-834).
Actin-Ring Formation
Cells were fixed for 15 min in warm 4% paraformaldehyde (PFA). After
fixation, cells were washed three times with PBS with 0.1% Triton
X-100 (PBST) and incubated with 0.2 U/ml rhodamine phalloidin
(Molecular Probes) for 30 min and washed again three times in PBST.
Statistical Analysis
Data were analyzed by two-tailed student’s t test. For all graphs, data
are represented as mean ± SEM.
Supplemental Data
Supplemental Data include Supplemental Experimental Proce-
dures and four figures and can be found with this article online at
http://www.cell.com/cgi/content/full/130/5/811/DC1/.
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